Binit 25/100/150 25 mg, 100 mg, 150 mg Tablets
PDF Leaflet Revision Date: 23 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of non-small cell lung cancer, bronchial adenocarcinoma, and pancreatic cancer.
Dosage (summary)
150 mg daily for NSCLC and bronchial adenocarcinoma; 100 mg daily with gemcitabine for pancreatic cancer.
Special Populations
- Hepatic impairment
- Renal impairment
- Elderly
- Paediatric use
Pregnancy & Breastfeeding
Avoid in pregnancy and breastfeeding; potential risks unknown.
Key Drug Interactions
- CYP3A4 inducers/inhibitors
- Warfarin
- Statins
Contraindications
- Severe hypersensitivity to erlotinib
Common side effects
- Rash
- Diarrhoea
- Fatigue
- Nausea
- Anorexia
Counselling Points
- Take at least 1 hour before or 2 hours after food
- Monitor for rash and diarrhoea
- Advise smoking cessation
Serious warnings
- Interstitial lung disease
- Gastrointestinal perforation
- Hepatic failure
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
